Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

The transaction furthers Globus Medical’s goal of becoming the preeminent musculoskeletal technology company in the world. Nevro’s comprehensive HFX spinal cord stimulation (SCS) platform ...

Following strong financial results revealed last month, US-headquartered Globus Medical has agreed to acquire spinal cord stimulation (SCS) company Nevro for $250m to reinforce its position in the ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target of $100.00. The company’s shares closed last ...

Stifel Nicolaus boosted their price objective on Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Roth Mkm boosted their price ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal ... Nevro’s comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and 4D Molecular Therapeutics (FDMT – Research Report).

Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...